NCT02930902View on ClinicalTrials.gov

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 20, 2017

Primary Completion Date

January 3, 2023

Study Completion Date

January 3, 2023

Conditions
Resectable Pancreatic CarcinomaStage I Pancreatic Cancer AJCC v6 and v7Stage IA Pancreatic Cancer AJCC v6 and v7Stage IB Pancreatic Cancer AJCC v6 and v7Stage II Pancreatic Cancer AJCC v6 and v7Stage IIA Pancreatic Cancer AJCC v6 and v7Stage IIB Pancreatic Cancer AJCC v6 and v7
Interventions
DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nab-paclitaxel

Given IV

DRUG

Paricalcitol

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgical resection of tumor

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02930902 - Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery | Biotech Hunter | Biotech Hunter